Natera (NTRA) stock price is $363.76, down 6.97% on the day, as of Nov 5, 2026. It has a market cap of $52.45Bn, and is classified in the Diagnostic Labs industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap52.45 Bn
P/E-272.62
FCF (Yr)109.11 Mn
ROA (Yr)-10.26
EV to EBIT-166.17
Net Income (Yr)-208.16 Mn
Enterprise Value48.13 Bn
Add ratio to table…
About
Natera, Inc. is a diagnostics company that applies proprietary molecular and bioinformatics technology to improve disease management worldwide. The company’s core technology combines cell free DNA analysis with statistical algorithms to detect genetic variations from very small samples. Natera focuses on three main healthcare areas oncology women’s health and organ health. It offers a suite of blood based tests that help clinicians make earlier and more targeted…
Natera, Inc. is a diagnostics company that applies proprietary molecular and bioinformatics technology to improve disease management worldwide. The company’s core technology combines cell free DNA analysis with statistical algorithms to detect genetic variations from very small samples. Natera focuses on three main healthcare areas oncology women’s health and organ health. It offers a suite of blood based tests that help clinicians make earlier and more targeted treatment decisions.
Natera generates revenue primarily from the sale of its diagnostic tests. Product revenues were $2,295.8 million in 2025, $1,685.1 million in 2024, and $1,068.5 million in 2023. The company sells tests directly through its U. S. sales force and partners with over one hundred laboratory and distribution partners internationally. In 2025 the company processed approximately 3,500,000 tests compared to 3,100,000 in 2024 and 2,500,000 in 2023. Revenue also includes service offerings such as the Constellation cloud software platform.
The company operates through the following segments.
Oncology: The segment provides personalized circulating tumor DNA tests for minimal residual disease detection recurrence monitoring and treatment response evaluation in patients previously diagnosed with cancer. It also offers tissue based comprehensive genomic profiling to support therapy selection and a hereditary cancer screening panel to inform surgical and therapeutic decisions.
Women's Health: The segment offers non invasive prenatal testing to screen for fetal chromosomal abnormalities and microdeletions. It also provides carrier screening for inherited conditions and single gene non invasive prenatal tests for recessive disorders. Additionally the segment includes hereditary cancer screening and products of conception testing to support reproductive health.
Organ Health: The segment offers tests to assess active rejection in kidney heart and lung transplant recipients by measuring donor derived cell free DNA in blood. It also provides a genetic test for chronic kidney disease to identify hereditary risk and guide management.
Natera holds a leading position in the non invasive prenatal testing market where it ranks as the largest volume provider in the United States. The company competes with firms such as BGI BillionToOne Fulgent Genetics Illumina through its Verinata subsidiary Labcorp Myriad Genetics Quest Diagnostics Revvity Guardant Health Tempus Labs Caris Life Sciences Exact Sciences Personalis and CareDx. Competitive advantages stem from its proprietary molecular assays and algorithms that deliver high sensitivity and specificity across oncology women’s health and organ health applications. A strong intellectual property portfolio with over 650 issued or pending patents and extensive peer reviewed publications further differentiate the company. Additionally Natera’s integrated commercial model which combines direct sales a global partnership network and user experience tools such as EMR integration and mobile phlebotomy supports broad adoption of its tests.
Natera serves hospitals outpatient clinics physician practices transplant centers oncology clinics IVF centers and clinical laboratories. Its tests are ordered by obstetricians gynecologists maternal fetal medicine specialists oncologists nephrologists and other healthcare providers. The company also works with biopharmaceutical firms for research use and collaborates with health plans to secure reimbursement coverage.
Sectors:Healthcare·TechnologySector rationaleNatera's primary revenue is derived from the sale of diagnostic tests for oncology, women's health, and organ health, which falls under the Diagnostic Equipment or Healthcare Services industries. A secondary sector of Technology is justified because the company sells the Constellation cloud software platform as a distinct service offering.Industries:Diagnostic LabsDiagnostic LabsPrimaryNatera operates as a diagnostics company that provides clinical laboratory and genetic testing services, generating the vast majority of its revenue from processing millions of tests. Its business model involves performing molecular and bioinformatics analysis on patient samples for oncology, women's health, and organ health, billing for these diagnostic-testing services.Healthcare ITHealthcare ITSecondaryThe company sells the Constellation cloud software platform, which is a healthcare-specific IT tool used to support the delivery and management of its diagnostic data.Classified using BQ-MICSCIK: 0001604821
Bull & bear
Investment Thesis
▲ Bull case
Natera, Inc. is positioned to unlock substantial upside in Signatera’s average selling price (ASP) beyond current guidance, driven by expanding Medicare coverage to additional histologies and growing private payer adoption, with leadership explicitly stating a long-term ASP target of $2,000 per test, which at current annualized volumes would generate an incremental $750 million in annual revenue and gross profit, yet the market appears to be modeling only modest ASP progression, failing to fully appreciate the runway from biomarker state laws and ongoing MolDx submissions for seven additional histologies that could meaningfully expand the covered base and accelerate pricing power.
The company’s Treatment on MRD (TOMR) strategy is emerging as a transformative economic and clinical lever, with real-world evidence from trials like INVIGOR011 showing 47% of bladder cancer patients avoiding $196,000-per-year adjuvant immunotherapy while maintaining 97% two-year overall survival, and similar cost-savings data in colorectal cancer demonstrating 21% to 43% system-wide savings from MRD-guided care, yet investors may be underestimating how this value proposition will drive rapid adoption across tumor types as payers increasingly recognize the economic utility of avoiding overtreatment, creating a self-reinforcing cycle of volume growth and pricing expansion.
Natera’s early cancer detection platform, particularly the FIND CRC study, is progressing ahead of schedule with enrollment on track for completion in Q3 2026, supporting a potential FDA PMA submission in 2027, and the company’s prior FORESEE CRC study demonstrated 22.5% sensitivity for advanced adenomas at 91.5% specificity in challenging sub-20mm lesions, indicating a differentiated ability to prevent cancer by intercepting precancerous growth, a capability that could establish Natera as a leader in the multi-cancer early detection (MCED) space long before competitors, yet the market may be treating this as a distant binary outcome rather than recognizing the accelerating inflection in enrollment and the strategic value of building a platform foundation for broader assays.
The Japan Signatera launch represents a near-term volume accelerator that is underappreciated in current models, with PMDA approval expected in Q2 2026 and commercial launch shortly thereafter, leveraging a market with comparable colorectal cancer incidence to the U.S., strong preclinical seeding through CIRCULATE-Japan and GALAXY studies involving over 150 institutions, supportive guidelines from JSMO and JASCO, and a single-payer system where one reimbursement decision can unlock nationwide access, yet consensus estimates may not be fully pricing in the potential for Japan to double Signatera’s annual CRC volume TAM over time, especially as expansion into histologies like MIBC builds on existing INVIGOR011 data.
Operational leverage is beginning to materialize as Natera scales, with management noting that SG&A growth is not keeping pace with revenue growth due to prior investments in sales headcount and AI-driven efficiencies, and the company’s deployment of significant AI capabilities across the business is expected to deliver further near-term efficiency gains, yet the market may be overlooking how this operating leverage will expand as volume growth continues, particularly given the company’s history of generating high ROIC on R&D investments and its ability to maintain leadership without proportional cost increases.
Natera, Inc. is positioned to unlock substantial upside in Signatera’s average selling price (ASP) beyond current guidance, driven by expanding Medicare coverage to additional histologies and growing private payer adoption, with leadership explicitly stating a long-term ASP target of $2,000 per test, which at current annualized volumes would generate an incremental $750 million in annual revenue and gross profit, yet the market appears to be modeling only modest ASP progression, failing to fully appreciate the runway from biomarker state laws and ongoing MolDx submissions for seven additional histologies that could meaningfully expand the covered base and accelerate pricing power.
The company’s Treatment on MRD (TOMR) strategy is emerging as a transformative economic and clinical lever, with real-world evidence from trials like INVIGOR011 showing 47% of bladder cancer patients avoiding $196,000-per-year adjuvant immunotherapy while maintaining 97% two-year overall survival, and similar cost-savings data in colorectal cancer demonstrating 21% to 43% system-wide savings from MRD-guided care, yet investors may be underestimating how this value proposition will drive rapid adoption across tumor types as payers increasingly recognize the economic utility of avoiding overtreatment, creating a self-reinforcing cycle of volume growth and pricing expansion.
Natera’s early cancer detection platform, particularly the FIND CRC study, is progressing ahead of schedule with enrollment on track for completion in Q3 2026, supporting a potential FDA PMA submission in 2027, and the company’s prior FORESEE CRC study demonstrated 22.5% sensitivity for advanced adenomas at 91.5% specificity in challenging sub-20mm lesions, indicating a differentiated ability to prevent cancer by intercepting precancerous growth, a capability that could establish Natera as a leader in the multi-cancer early detection (MCED) space long before competitors, yet the market may be treating this as a distant binary outcome rather than recognizing the accelerating inflection in enrollment and the strategic value of building a platform foundation for broader assays.
The Japan Signatera launch represents a near-term volume accelerator that is underappreciated in current models, with PMDA approval expected in Q2 2026 and commercial launch shortly thereafter, leveraging a market with comparable colorectal cancer incidence to the U.S., strong preclinical seeding through CIRCULATE-Japan and GALAXY studies involving over 150 institutions, supportive guidelines from JSMO and JASCO, and a single-payer system where one reimbursement decision can unlock nationwide access, yet consensus estimates may not be fully pricing in the potential for Japan to double Signatera’s annual CRC volume TAM over time, especially as expansion into histologies like MIBC builds on existing INVIGOR011 data.
Operational leverage is beginning to materialize as Natera scales, with management noting that SG&A growth is not keeping pace with revenue growth due to prior investments in sales headcount and AI-driven efficiencies, and the company’s deployment of significant AI capabilities across the business is expected to deliver further near-term efficiency gains, yet the market may be overlooking how this operating leverage will expand as volume growth continues, particularly given the company’s history of generating high ROIC on R&D investments and its ability to maintain leadership without proportional cost increases.
Natera, Inc. faces persistent profitability challenges despite revenue growth, as evidenced by a Q1 2026 net loss of $85.1 million and an operating loss of $93.5 million, with management acknowledging that gross margin expansion is being held back by transient but recurring factors such as work-in-process inventory buildup during high-volume quarters and non-cash charges from acquisitions like Foresight, suggesting that the path to sustainable profitability remains uncertain even as the company raises guidance, and the market may be overestimating the durability of margin improvement without concrete evidence of operating leverage scaling at the expected rate.
The company’s growth is increasingly dependent on Signatera in oncology, yet the business remains heavily reliant on women’s health for seasonal volume strength, with Q1 traditionally being the strongest quarter due to seasonality, and while oncology grew 55% year-over-year in Q1, the overall business still shows pronounced quarterly variability, raising concerns that any slowdown in women’s health adoption—whether due to competitive pressures, pricing dynamics, or shifts in prenatal screening guidelines—could disproportionately impact overall performance, especially as the core Horizon and Panorama businesses face intensifying competition in a crowded NIPT market.
Reimbursement and coverage risks remain underappreciated, particularly for Signatera in emerging indications, as management noted that while many histologies are in submission to Medicare, the standard coverage review cycle creates uncertainty around timing and breadth of approval, and although biomarker state laws offer a pathway to commercial payer compliance, the actual pace of adoption and ASP realization depends on complex negotiations with individual payers, meaning that the long-term ASP target of $2,000 per test is contingent on numerous external factors beyond the company’s control, and investors may be assuming a smoother, faster rollout than what the historical pace of MolDx submissions and coverage decisions suggests.
The FIND CRC early cancer detection study, while progressing ahead of schedule, still carries significant binary risk, with a potential FDA PMA readout not expected until 2027, and despite promising precursor data from FORESEE CRC, the pivotal trial’s success is not guaranteed, especially given the historical challenges of blood-based screening in detecting advanced adenomas, and if the study fails to meet its endpoints, Natera could face substantial sunk costs in R&D and commercialization without a near-term offsetting revenue stream, yet the market may be pricing in too much optimism about the study’s outcome without adequately weighing the clinical and regulatory hurdles inherent in validating a new screening modality.
International expansion, particularly the Japan launch, while promising, faces execution risks related to pricing negotiations with the Ministry of Health, reimbursement delays, and slower-than-expected adoption despite preclinical seeding through studies like CIRCULATE-Japan, and although Japanese medical society guidelines support MRD testing, the actual commercial ramp depends on securing favorable pricing and broad formulary access, which could take longer than anticipated, meaning that the expected volume acceleration may be delayed or dampened, and investors could be overestimating the near-term impact of international markets on overall growth.
Natera, Inc. faces persistent profitability challenges despite revenue growth, as evidenced by a Q1 2026 net loss of $85.1 million and an operating loss of $93.5 million, with management acknowledging that gross margin expansion is being held back by transient but recurring factors such as work-in-process inventory buildup during high-volume quarters and non-cash charges from acquisitions like Foresight, suggesting that the path to sustainable profitability remains uncertain even as the company raises guidance, and the market may be overestimating the durability of margin improvement without concrete evidence of operating leverage scaling at the expected rate.
The company’s growth is increasingly dependent on Signatera in oncology, yet the business remains heavily reliant on women’s health for seasonal volume strength, with Q1 traditionally being the strongest quarter due to seasonality, and while oncology grew 55% year-over-year in Q1, the overall business still shows pronounced quarterly variability, raising concerns that any slowdown in women’s health adoption—whether due to competitive pressures, pricing dynamics, or shifts in prenatal screening guidelines—could disproportionately impact overall performance, especially as the core Horizon and Panorama businesses face intensifying competition in a crowded NIPT market.
Reimbursement and coverage risks remain underappreciated, particularly for Signatera in emerging indications, as management noted that while many histologies are in submission to Medicare, the standard coverage review cycle creates uncertainty around timing and breadth of approval, and although biomarker state laws offer a pathway to commercial payer compliance, the actual pace of adoption and ASP realization depends on complex negotiations with individual payers, meaning that the long-term ASP target of $2,000 per test is contingent on numerous external factors beyond the company’s control, and investors may be assuming a smoother, faster rollout than what the historical pace of MolDx submissions and coverage decisions suggests.
The FIND CRC early cancer detection study, while progressing ahead of schedule, still carries significant binary risk, with a potential FDA PMA readout not expected until 2027, and despite promising precursor data from FORESEE CRC, the pivotal trial’s success is not guaranteed, especially given the historical challenges of blood-based screening in detecting advanced adenomas, and if the study fails to meet its endpoints, Natera could face substantial sunk costs in R&D and commercialization without a near-term offsetting revenue stream, yet the market may be pricing in too much optimism about the study’s outcome without adequately weighing the clinical and regulatory hurdles inherent in validating a new screening modality.
International expansion, particularly the Japan launch, while promising, faces execution risks related to pricing negotiations with the Ministry of Health, reimbursement delays, and slower-than-expected adoption despite preclinical seeding through studies like CIRCULATE-Japan, and although Japanese medical society guidelines support MRD testing, the actual commercial ramp depends on securing favorable pricing and broad formulary access, which could take longer than anticipated, meaning that the expected volume acceleration may be delayed or dampened, and investors could be overestimating the near-term impact of international markets on overall growth.